Company intelligence / Profile preview

Dynogen Pharmaceuticals, Inc.

Waltham, Massachusetts, United Statesastellas.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company had multiple clinical programs including DDP733 (pumosetrag) for IBS-c which entered Phase 2b trials, DDP225 which showed positive results in Phase 2a for IBS-d with 71% response rate vs 25% for placebo, and DDP200 for overactive bladder. The company was placed in administration in February 2009 after failing to secure financing when clinical data in one program was not sufficiently positive.[1][6][9]

Therapeutic areas: GastroenterologyMen's Health
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

pumosetrag

1 more asset in the full pipeline.

Request access →

Partnerships

Evotec OAIAstellas Pharma Inc.

Beyond the preview

Go deeper on Dynogen Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynogen Pharmaceuticals, Inc..

Explore the full profile